Related Experiment Videos

Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes

Takahide Kohro1, Dobun Hayashi, Tsutomu Yamazaki

  • 1Department of Translational Research for Healthcare and Clinical Science, The University of Tokyo, Tokyo, Japan.

Circulation Journal : Official Journal of the Japanese Circulation Society
|March 18, 2010
PubMed

Insights

Beta-blockers are underprescribed for coronary artery disease (CAD) patients in Japan. However, lipophilic beta-blockers may reduce mortality risk, warranting further investigation in clinical trials.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blocker underprescription is noted in Japanese coronary artery disease (CAD) patients.
  • Established evidence supports beta-blocker benefits in CAD management.

Purpose of the Study:

  • To investigate beta-blocker utilization in a large cohort of Japanese CAD patients.
  • To evaluate the effectiveness of beta-blockers in reducing mortality and adverse events.

Main Methods:

  • Analysis of 13,812 patients with angiographically confirmed CAD.
  • Propensity score matching to assess beta-blocker impact on mortality and events.
  • Comparison of lipophilic versus hydrophilic beta-blockers.

Main Results:

  • Beta-blockers were prescribed at discharge to 30.1% of patients.
  • High continuation rate (90.8%) observed for beta-blockers.
  • No significant reduction in all-cause mortality, cardiac, or cerebrovascular events with beta-blockers overall.
  • Lipophilic beta-blockers showed a significant reduction in all-cause mortality compared to hydrophilic ones.

Conclusions:

  • Despite low initial prescription rates, beta-blockers demonstrate high adherence in Japanese CAD patients.
  • Lipophilic beta-blockers may offer superior mortality benefits over hydrophilic agents.
  • Further randomized controlled trials are necessary to confirm the differential efficacy of lipophilic beta-blockers.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...